High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A Le CesneJ Genin

Abstract

The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen. Between January 1991 and November 1993, 40 patients with progressive ASTS were entered onto the study. Twenty-eight patients had been pretreated with a multidrug regimen that contained SDI and were classified as follows: SDI-refractory (n = 21), SDI-resistant (n = 2), and indeterminate SDI-sensitive (n = 5). Patients were treated until progression or major toxicity. One hundred forty-seven cycles of HDI were administered. Neutropenia was dose-limiting, with 100% of patients experiencing grade 3 to 4 toxicity and 12 admissions for febrile neutropenia (30% of patients). Neurotoxicity (17% of patients) was significantly associated with acute renal failure (n = 4) (P < .001), grade 4 thrombocytopenia (P < .01) and febrile neutropenia (P = .048). Chronic renal toxicity (n = 4) was significantly associated with retroperitoneal masses and/or prior nephrectomy (P = .008). Partial responses (PRs) were observed in 12 of 36...Continue Reading

Citations

Feb 20, 1999·American Journal of Clinical Oncology·O MerimskyA Le Cesne
Aug 3, 1999·Acta Orthopaedica Scandinavica. Supplementum·J O FernbergH Strander
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A YovineJ L Misset
May 10, 2013·Expert Review of Anticancer Therapy·Axel Le Cesne
May 15, 2013·Journal of Cancer Research and Clinical Oncology·F PlonerT Brodowicz
Jun 5, 2015·Future Oncology·Giovanni GrignaniPeter Reichardt
Jun 20, 2015·Sarcoma·Frédéric AmantPatricia Pautier
Jan 1, 2015·Rare Cancers and Therapy·Samia ArifiNabil Ismaili
Nov 1, 2016·Current Opinion in Urology·Przemyslaw AdamczykT Drewa
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L HensleyD G Pfister
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S DelalogeE Cvitkovic
Dec 2, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P PautierC Lhommé
Dec 2, 2004·Expert Opinion on Emerging Drugs·Werner Fahn, Rolf D Issels
Oct 13, 2006·British Journal of Cancer·S LeyvrazUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
Jul 22, 2004·Pediatric Blood & Cancer·Jeremy S WhelanUNKNOWN London Bone and Soft Tissue Tumour Service
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Le CesneO S Nielsen
Mar 2, 2011·Current Treatment Options in Oncology·Michelle Scurr
May 6, 2015·Current Treatment Options in Oncology·Scott M Norberg, Sujana Movva
Dec 3, 2016·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A López-PousaX Garcia Del Muro
Feb 17, 2018·Therapeutic Advances in Medical Oncology·Alessandro De VitaToni Ibrahim
Dec 10, 1997·American Journal of Clinical Oncology·M VarterasianC Karanes
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Y BlayP Biron
Sep 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B E PlaatW T van der Graaf
Jan 1, 1997·Journal of Cancer Research and Clinical Oncology·E C BrainJ L Misset
May 2, 2003·Expert Review of Anticancer Therapy·Lara Maria PasettoAlba Ariela Brandes
Jan 30, 2015·Clinical Sarcoma Research·Roberta SanfilippoPaolo Giovanni Casali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Paul LoriganEuropean Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
Annals of Oncology : Official Journal of the European Society for Medical Oncology
R PalumboS Toma
© 2021 Meta ULC. All rights reserved